Welcome to MolDiag-PaCa
1) Vimalachandran D., Greenhalf W., Watson R., Thompson C., Prime W., Campbell F., Dodson A., Lemoine NR. Crnogorac-Jurcevic T., Neoptolemos JP., Costello, E. Nuclear S100A6 is associated with poor survival in pancreatic cancer Cancer Research 2005; 65:3218-25.

2) Yan L, McFaul C, Howes N, Leslie J, Lancaster G, Wong T, Evans J, Gilmore I, Smart H, Lombard M, Neoptolemos J, Greenhalf W. Molecular Analysis To Detect Pancreatic Ductal Adenocarcinoma In High Risk Groups. Gastroenterology 2005;128:2124-30.

3) Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, Beger H, Fernandez-Cruz L, Dervenis C, Lacaine F, Falconi M, Pederzoli P, Pap A, Spooner D, Kerr DJ, Büchler MW for the members of the European Study Group for Pancreatic Cancer (ESPAC). The final results of the European Study Group for Pancreatic Cancer randomized controlled trial of adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer. N Engl J Med 2004; 350:1200-10.

4) Hahn SA, Greenhalf B, Ellis I, Sina-Frey M, Rieder H, Korte B, Gerdes B, Kress R, Ziegler A, Raeburn JA, Campra D, Grutzmann R, Rehder H, Rothmund M, Schmiegel W, Neoptolemos JP, Bartsch DK. BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst 2003;95:214-21.

5) Shekouh AR, Thompson CC, Prime W, Campbell F, Hamlett J, Herrington CS, Lemoine NR, Tatjana Crnogorac-Jurcevic, Buechler MW, Friess H, Neoptolemos JP, Pennington SR, Costello E. Application of laser capture microdissection combined with two-dimensional electrophoresis for the discovery of differentially regulated proteins in pancreatic ductal adenocarcinoma. Proteomics 2003; 3:1988.